Low-dose radiation for posttransplant lymphoproliferative disorder

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 2, 2003, Pages 210-214

  Kang, Song K ^a   Kirkpatrick, John P ^b   Halperin, Edward C ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Bone marrow transplant; EBV; Lymphoma; Posttransplant lymphoproliferative disorder; Radiation therapy

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; FOSCARNET; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ACUTE TOXICITY; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CASE REPORT; CAUSE OF DEATH; DYSKERATOSIS CONGENITA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW ENERGY RADIATION; LUNG HEMORRHAGE; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALE; MEDIASTINUM MASS; MYCOSIS; PRESCHOOL CHILD; RADIATION DOSE; RADIATION SICKNESS; SCHOOL CHILD; UMBILICAL CORD;

ADULT; BONE MARROW TRANSPLANTATION; CHILD; HUMANS; IMMUNOSUPPRESSION; LYMPHATIC IRRADIATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; PALLIATIVE CARE; RADIOTHERAPY DOSAGE;

EID: 0037394599     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200304000-00023     Document Type: Article

References (22)

1. Morrison VA, Dunn DL, Manivel JC, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994;97:14-24.
2. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990;323:1723-8.
3. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995;13:961-8.
4. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988;45:719-27.
5. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988;72:520-9.
6. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:1234-43.
7. Hanto DW, Sakamoto K, Purilo DT, et al. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Clinical, pathologic, and virologic correlation. Surgery 1981;90:204-13.
8. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989;321:1080-5.
9. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995;85:552-65.
10. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;8377:583-7.
11. Swinnen LJ. Overview of posttransplant B-cell lymphoproliferative disorders. Semin Oncol 1999;26:21-5.
12. Opelz G. Are post-transplant lymphomas inevitable? Nephrol Dial Transplant 1996;11:1952-5.
13. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982;306:913-8.
14. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-91.
15. Fischer A, Blanche S, Bidois JL, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991;324:1451-6.
16. Benkerrou M, Jais J, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998;92:3137-47.
17. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11:113-6.
18. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000;96:4055-63.
19. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989;321:784-9.
20. Koffman BH, Kennedy AS, Heyman M, et al. Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation. Int J Cancer (Radiat Oncol Invest) 2000;90:104-9.
21. Tsai DE, Stadtmauer EA, Canaday DJ, et al. Combined radiation and chemotherapy in posttransplant lymphoproliferative disorder. Med Oncol 1998;15:279-81.
22. Ho M, Miller G, Atchison R, et al. Epstein-Barr virus infections and DNA hybridization studies in post-transplantation lymphoma and lymphoproliferative lesions: role of primary infection. J Infect Dis 1985;152:876-86.